Latest Industry Updates
From company milestones to industry breakthroughs, uncover the stories making waves and shaping the narrative in real time.
- Press Release
“I KNOW ICH E6 (R2) COMPLIANCE INSISTS ON A RISK-BASED APPROACH TO RUNNING MY TRIALS, BUT...
- Featured Article
A risk-based approach to clinical research may include a central statistical assessment of data quality.
...Source: Sage Journals
- Press Release
Strategic collaboration leverages CluePoints’ Central Statistical Monitoring (CSM) technology to enhance data quality and reduce operational...
- Featured Article
Not only is there a significant good clinical practice (GCP) expectation, Risk-Based Monitoring (RBM) presents a...
Source: Contract Pharma
- Press Release
WAYNE, PA – April 09, 2019: CluePoints, a leading provider of Risk-Based Study Execution(RBx) and Data...
- Featured Article
Since finalizing its risk-based monitoring guidance in 2013, the FDA is providing additional information in a...
Source: Outsourcing Pharma
- Press Release
We’re delighted to announce that registration for CluePoints’ US Risk-Based Quality Management Roadshow is now open....
- Featured Article
Since the introduction of the ICH E6 (R2) addendum, the industry has seen a rise in...
Source: Pharma Focus Asia
- Featured Article
The ICH E6 R2 Addendum is starting to have a significant, positive impact on clinical trial...
Source: Contract Pharma
- Featured Article
In the clinical trials industry there is a tendency to watch and wait, which has been...
Source: PharmaIQ
- Press Release
Are you struggling with how to assess the true value of improving data quality and integrity...
- Press Release
The other week, CluePoints in conjunction with HighPoint Solutions delivered 3 European Roadshows in Basel, Copenhagen...